Literature DB >> 11766739

Adjuvant chemotherapy in early stage uterine sarcomas: an open question.

A Gadducci1, A Romanini.   

Abstract

Uterine sarcomas are aggressive gynecological cancers even at early stage of disease. The most common histological types are represented by leiomyosarcoma, endometrial stromal sarcoma, and carcinosarcoma. The mainstay of treatment of stage I-II disease is total hysterectomy with bilateral salpingo-oophorectomy. Adjuvant radiotherapy may decrease local recurrence rates without any significant impact on survival. Adjuvant chemotherapy is a logical approach, since distant recurrences are more frequent than local failures. The chemotherapy regimens commonly used in advanced uterine sarcomas are similar to the ones for advanced soft tissue sarcomas, with anthracyclines and ifosfamide as the most active drugs. However, carcinosarcomas respond better to cisplatin-based regimens. It is advisable to design international cooperative randomized trials with the aim of defining the role of adjuvant chemotherapy in the treatment of early stage uterine sarcomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11766739

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  9 in total

Review 1.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

2.  Concomitant endometrial and pancreatic cancers.

Authors:  S Michelle Shiller; Shawna L Bull Phelps; Jeffrey P Lamont; Granger R Scruggs
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04

3.  Primary splenic carcinosarcoma with local invasion of chest wall: a rare case.

Authors:  Ting Sun; Gui-Feng Wang; Yun Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2017 Aug.       Impact factor: 3.066

4.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

5.  The reasonable timing of the adjuvant radiotherapy in the treatment of uterine carcinosarcoma according to the surgical intent: suggestion based on progression patterns.

Authors:  Jeong Il Yu; Doo Ho Choi; Seung Jae Huh; Won Park; Dongryul Oh; Duk Soo Bae
Journal:  Radiat Oncol J       Date:  2013-06-30

6.  Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.

Authors:  Jeong-Yeol Park; Dae-Yeon Kim; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-28       Impact factor: 4.553

7.  A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Authors:  Elizabeth L Dickson; Rachel Isaksson Vogel; Paola A Gehrig; Stuart Pierce; Laura Havrilesky; Angeles Alvarez Secord; Joseph Dottino; Amanda N Fader; Stephanie Ricci; Melissa A Geller
Journal:  Gynecol Oncol       Date:  2015-09-06       Impact factor: 5.482

8.  Clinicopathological and molecular markers associated with prognosis and treatment effectiveness of endometrial stromal sarcoma: a retrospective study in China.

Authors:  Li He; Jun-Dong Li; Ying Xiong; Xin Huang; Long Huang; Jia-xin Lin; Yun Zhou; Min Zheng
Journal:  Arch Gynecol Obstet       Date:  2014-02       Impact factor: 2.344

9.  Microarray analysis on gene regulation by estrogen, progesterone and tamoxifen in human endometrial stromal cells.

Authors:  Chun-E Ren; Xueqiong Zhu; Jinping Li; Christian Lyle; Sean Dowdy; Karl C Podratz; David Byck; Hai-Bin Chen; Shi-Wen Jiang
Journal:  Int J Mol Sci       Date:  2015-03-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.